RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Apellis Pharmaceuticals Stock

Apellis Pharmaceuticals EBIT 2024

Apellis Pharmaceuticals EBIT

-139.5 M USD

Ticker

APLS

ISIN

US03753U1060

WKN

A2JAAW

In 2024, Apellis Pharmaceuticals's EBIT was -139.5 M USD, a -73.02% increase from the -517.12 M USD EBIT recorded in the previous year.

The Apellis Pharmaceuticals EBIT history

YEAREBIT (undefined USD)
2030e2.08
2029e1.78
2028e0.92
2027e0.66
2026e0.36
2025e0.05
2024e-0.14
2023-0.52
2022-0.59
2021-0.54
2020-0.21
2019-0.29
2018-0.13
2017-0.05
2016-0.03
2015-0.02
2014-0.01
2013-0

Apellis Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Apellis Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Apellis Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Apellis Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Apellis Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Apellis Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Apellis Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Apellis Pharmaceuticals’s growth potential.

Apellis Pharmaceuticals Revenue, EBIT and net profit per share

DateApellis Pharmaceuticals RevenueApellis Pharmaceuticals EBITApellis Pharmaceuticals Net Income
2030e3.67 B undefined2.08 B undefined1.86 B undefined
2029e2.5 B undefined1.78 B undefined821.53 M undefined
2028e2.15 B undefined919.24 M undefined738.25 M undefined
2027e1.9 B undefined660.33 M undefined635.02 M undefined
2026e1.13 B undefined361.47 M undefined146.39 M undefined
2025e882.51 M undefined52.26 M undefined-106.89 M undefined
2024e775.68 M undefined-139.5 M undefined-213.23 M undefined
2023396.59 M undefined-517.12 M undefined-528.63 M undefined
202275.4 M undefined-594.6 M undefined-652.2 M undefined
202166.6 M undefined-536.3 M undefined-746.4 M undefined
2020250.6 M undefined-213.7 M undefined-344.9 M undefined
20190 undefined-288 M undefined-304.7 M undefined
20180 undefined-127.9 M undefined-127.5 M undefined
20170 undefined-50.8 M undefined-51 M undefined
20160 undefined-27.3 M undefined-27.1 M undefined
20150 undefined-20.1 M undefined-46.5 M undefined
20140 undefined-11.3 M undefined-10.8 M undefined
20130 undefined-4 M undefined-4 M undefined

Apellis Pharmaceuticals stock margins

The Apellis Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Apellis Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Apellis Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Apellis Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Apellis Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Apellis Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Apellis Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Apellis Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Apellis Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Apellis Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Apellis Pharmaceuticals Margin History

Apellis Pharmaceuticals Gross marginApellis Pharmaceuticals Profit marginApellis Pharmaceuticals EBIT marginApellis Pharmaceuticals Profit margin
2030e85.25 %56.6 %50.66 %
2029e85.25 %71.39 %32.87 %
2028e85.25 %42.7 %34.29 %
2027e85.25 %34.72 %33.39 %
2026e85.25 %31.9 %12.92 %
2025e85.25 %5.92 %-12.11 %
2024e85.25 %-17.98 %-27.49 %
202385.25 %-130.39 %-133.29 %
202292.57 %-788.59 %-864.99 %
202192.19 %-805.26 %-1,120.72 %
202090.02 %-85.28 %-137.63 %
201985.25 %0 %0 %
201885.25 %0 %0 %
201785.25 %0 %0 %
201685.25 %0 %0 %
201585.25 %0 %0 %
201485.25 %0 %0 %
201385.25 %0 %0 %

Apellis Pharmaceuticals Aktienanalyse

What does Apellis Pharmaceuticals do?

Apellis Pharmaceuticals was founded in 2009 and is headquartered in Waltham, Massachusetts, USA. The company is a biopharmaceutical company specializing in developing innovative therapies for serious diseases of the immune system and the eyes. The company's focus is on developing therapies for rare and difficult-to-treat diseases. Apellis relies on a cellular science platform based on the discovery of new biological mechanisms. In the field of ophthalmology, Apellis is developing therapies for rare retinal diseases such as geographic atrophy, a progressive disease that can lead to blindness. The company has developed a new drug called APL-2, which is currently being tested in clinical trials. APL-2 inhibits the complement system, an important component of the immune system that plays a crucial role in retinal diseases. In the field of immunology, Apellis is working on developing therapies for autoimmune diseases, where the immune system attacks the body's own tissues. One such disease is paroxysmal nocturnal hemoglobinuria (PNH), which can lead to destruction of red blood cells. Apellis has developed a drug called APL-2, which inhibits the complement system and stops the breakdown of red blood cells. APL-2 is also being investigated for other autoimmune diseases such as the rare blood disorder syndrome, thrombotic microangiopathy syndrome. Apellis is also developing a therapy for chronic obstructive pulmonary disease (COPD), which can cause survival problems in advanced stages. The research focus is on identifying targets in the complement system and developing therapeutics to inhibit these targets. Apellis' business model is based on a collaborative approach, working closely with patient support groups to better understand patient needs and develop a deep physiological understanding of disease mechanisms to explore more effective therapy approaches. Apellis also collaborates with biotechnology partners and suppliers to accelerate the development of its drugs and reduce costs. Apellis has a strong financing base and has conducted several successful investment rounds in recent years. In 2017, the company raised $150 million in a Series E investment round. In 2019, Apellis received a $250 million investment from Swiss Re, one of the world's largest reinsurance companies, for a 10% stake in the company. This investment provides Apellis with the financial stability necessary for accelerated drug development. In 2020, Apellis obtained approval for APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the EU. In the same year, the company also obtained accelerated approval for APL-2 for the treatment of synergenic constipation syndrome. In summary, Apellis Pharmaceuticals is an innovative biopharmaceutical company specializing in the development of therapies for rare and difficult-to-treat diseases of the immune system and the eyes. With a strong financing base and a wide range of products, the company is well positioned to fully leverage the potential of its cellular science platform and provide innovative treatment options for patients. Apellis Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Apellis Pharmaceuticals's EBIT

Apellis Pharmaceuticals's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Apellis Pharmaceuticals's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Apellis Pharmaceuticals's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Apellis Pharmaceuticals’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Apellis Pharmaceuticals stock

How much did Apellis Pharmaceuticals achieve in EBIT for the current year?

In the current year, Apellis Pharmaceuticals has achieved an EBIT of -139.5 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Apellis Pharmaceuticals.

How has the EBIT of Apellis Pharmaceuticals developed in recent years?

The EBIT of Apellis Pharmaceuticals has increased by -73.024% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Apellis Pharmaceuticals?

The EBIT of Apellis Pharmaceuticals is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Apellis Pharmaceuticals pay?

Over the past 12 months, Apellis Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Apellis Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Apellis Pharmaceuticals?

The current dividend yield of Apellis Pharmaceuticals is .

When does Apellis Pharmaceuticals pay dividends?

Apellis Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Apellis Pharmaceuticals?

Apellis Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Apellis Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Apellis Pharmaceuticals located?

Apellis Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Apellis Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Apellis Pharmaceuticals from 11/15/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/15/2024.

When did Apellis Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/15/2024.

What was the dividend of Apellis Pharmaceuticals in the year 2023?

In the year 2023, Apellis Pharmaceuticals distributed 0 USD as dividends.

In which currency does Apellis Pharmaceuticals pay out the dividend?

The dividends of Apellis Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Apellis Pharmaceuticals

Our stock analysis for Apellis Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Apellis Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.